Gilead Sciences, Inc. (GILD) Covered Calls

Gilead Sciences, Inc. covered calls Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. By 2026, Gilead has successfully transitioned from a pure-play virology firm to a diversified leader in HIV, oncology, and liver diseases. Under CEO Daniel O’Day, the company is scaling its twice-yearly injectable Yeztugo (lenacapavir) and expanding its antibody-drug conjugate (ADC) portfolio through Trodelvy.

You can sell covered calls on Gilead Sciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GILD (prices last updated Wed 4:16 PM ET):

Gilead Sciences, Inc. (GILD) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
152.74 -2.53 152.45 154.03 4.6M 24 193
Covered Calls For Gilead Sciences, Inc. (GILD)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 152.5 0.92 153.11 -0.4% -48.7%
Mar 20 155 3.60 150.43 2.9% 34.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Gilead operates a highly profitable franchise centered on antiviral leadership and a rapidly maturing oncology pipeline. In 2026, the company achieved record margins following a strategic manufacturing and pricing agreement with the U.S. government. Their primary segments include:

  1. HIV Franchise: The company's primary revenue driver, led by Biktarvy and the 2025 approval of Yeztugo (lenacapavir), the world’s first twice-yearly injectable for HIV prevention (PrEP).
  2. Oncology & Cell Therapy: A high-growth segment featuring Trodelvy for breast and lung cancer, and its Kite Pharma subsidiary, which leads the CAR-T market with Yescarta and Tecartus.
  3. Liver Disease & COVID-19: Comprising leading treatments for Hepatitis C (Epclusa), Hepatitis B, and the antiviral Veklury (remdesivir), which remains a standard of care for hospitalized COVID-19 patients.

Competitive Landscape

Gilead faces intense competition from global pharmaceutical giants and innovative biotech firms. In the HIV market, its most direct rival is ViiV Healthcare (a joint venture of GSK and Pfizer). In oncology and cell therapy, it competes with Bristol Myers Squibb, AstraZeneca, and Merck, the latter of which partners with Gilead on long-acting oral HIV treatments. For diversified biotech exposure, it is frequently compared to Amgen and Regeneron. As a "Dividend King" in the making, Gilead’s strong cash flow and 2.2% yield provide a competitive moat against smaller, pre-profit biotech challengers.

Strategic Outlook and Innovation

The 2026 strategic roadmap for Gilead is defined by "The Precision Oncology Pivot." Following its 2026 licensing deal with Repare Therapeutics, Gilead is utilizing Generative AI via the Genesis Therapeutics platform to discover small molecules for "undruggable" cancer targets. A major focus is TrumpRx.gov integration; under a late-2025 federal agreement, Gilead provides discounted access to its Hepatitis C and HIV medicines in exchange for a three-year exemption from specific pharmaceutical tariffs. In 2026, the company reached a 35% non-GAAP operating margin, fueled by the lower-cost production of its "Purpose" clinical program. With a robust $32 billion five-year U.S. investment plan, Gilead aims to dominate the "long-acting" therapeutic era, shifting the patient experience from daily pills to seasonal injections while maintaining its position as a top-tier cash-flow machine for shareholders.